<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173535</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5590</org_study_id>
    <nct_id>NCT02173535</nct_id>
  </id_info>
  <brief_title>Quantitative Study of New Limbal Ring Prototypes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test five new soft contact lens color pattern variants to determine
      whether the test lens makes the wearers eyes look bigger, more defined or enhances their
      overall appearance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2014</start_date>
  <completion_date type="Actual">June 1, 2014</completion_date>
  <primary_completion_date type="Actual">June 1, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subject in Agreement (Bigger Eyes)</measure>
    <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
    <description>Subjects' responses to the question &quot;Make my eye look bigger&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subject in Agreement (Defines Eyes)</measure>
    <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
    <description>Subjects' responses to the question &quot;Define my eye&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subject in Agreement (Enhance Eyes)</measure>
    <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
    <description>Subjects' responses to the question &quot;Enhance my overall appearance&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Cosmetic Effect</condition>
  <arm_group>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon test contact lens Variant AP</intervention_name>
    <description>Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.</description>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon test contact lens Variant JG</intervention_name>
    <description>Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.</description>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon test contact lens Variant CS</intervention_name>
    <description>Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.</description>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon test contact lens Variant VC</intervention_name>
    <description>Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.</description>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon test contact lens Variant LA</intervention_name>
    <description>Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.</description>
    <arm_group_label>etafilcon test contact lens Variant AP</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant JG</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant CS</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant VC</arm_group_label>
    <arm_group_label>etafilcon test contact lens Variant LA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be at least 18 years of age and no more than 39 years of age
             (inclusive)

          2. Subjects must be Asian female

          3. Subjects must be able to read Chinese

          4. Subjects' monthly household income must be above HKD$ 10,000

          5. Subjects must be habitual soft contact lens wearer or habitual limbal lens wearer or
             have a history of previous habitual lens wear.

          6. Subjects' current/previous habitual lens must be in the disposable soft lens modality
             (ranging from daily to monthly)

          7. Subjects must have dark colored iris (black, brown, or brown hazel)

          8. Subjects must be &quot;concept acceptors&quot;. Concept acceptors are subjects that are willing
             to try new circle contact lenses.

          9. Subjects must be classified as either 'Classic' or 'Vogue' on a Pattern Evaluation
             Screening Questionnaire.

         10. Subjects must have acceptable near vision (without vision correction) and be able to
             see the test article lenses in the mirror 30 cm or closer.

         11. Subjects must have best corrected visual acuity of 20/40 (Snellen or equivalent) or
             better in each eye.

         12. Subjects must possess a functional/usable pair of spectacles and bring them to the
             visit (only if applicable-to the investigators discretion)

         13. Subjects must read, understand, and sign the Statement of Informed Consent

         14. Subjects must appear able and willing to adhere to the instructions set forth in this
             clinical protocol

        Exclusion Criteria:

          1. Subjects, or subjects' family member within the same household, that work for the
             following entities/companies: Government, advertising, marketing research or
             consultancy, media or public relations, companies that make, distribute or sell
             eyewear or contact lenses, eyecare practice (optometrist, ophthalmologist, optician)
             or the research center conducting the study

          2. Habitual wearers of rigid gas permeable lenses within the last 3 months

          3. Habitual soft conventional contact lens wearers (conventional lenses defined as
             replacement modality of greater than 1 month)

          4. Any color deficiencies, by self report

          5. Currently pregnant or breast-feeding a baby

          6. Diabetes

          7. Any ocular or systemic allergies or diseases which may interfere with contact lens
             wear

          8. Any systemic disease, autoimmune disease, or use of medication which may interfere
             with contact lens wear, at the investigator's discretion

          9. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious
             immunosuppressive disease (e.g. HIV), by self report

         10. Any grade 3 or greater Biomicroscopy findings (this includes, corneal edema, corneal
             staining, corneal vascularization, conjunctival injection, tarsal abnormalities,
             bulbar injection) on the FDA classification scale

         11. Any active ocular abnormalities/conditions that may interfere with contact lens wear
             (this includes, but not limited to, chalazia, recurrent styes, pterygium, infection,
             etc.)

         12. Any corneal distortion or moderate or above corneal distortion by self report

         13. History of any corneal refractive surgery

         14. Habitual contact lens is multifocal, monovision or worn as extended wear
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hung Hom</city>
        <state>Kowloon</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>June 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 257 subjects were enrolled into this study. Of the enrolled subjects, 240 subjects were dispensed at least 1 study lenses, while 17 subjects failed to meet the eligibility criteria. No subjects were discontinued during the course of this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AP-CS-LA-JG-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P2">
          <title>AP-JG-CS-VC-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P3">
          <title>AP-LA-VC-CS-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P4">
          <title>AP-VC-JG-LA-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P5">
          <title>CS-AP-VC-JG-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P6">
          <title>CS-JG-AP-LA-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P7">
          <title>CS-VC-LA-AP-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P8">
          <title>CS-LA-JG-VC-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P9">
          <title>JG-AP-LA-VC-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P10">
          <title>JG-CS-VC-LA-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P11">
          <title>JG-LA-CS-AP-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P12">
          <title>JG-VC-AP-CS-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P13">
          <title>LA-AP-JG-CS-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P14">
          <title>LA-CS-AP-VC-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P15">
          <title>LA-JG-VC-AP-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P16">
          <title>LA-VC-CS-JG-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P17">
          <title>VC-AP-CS-LA-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P18">
          <title>VC-CS-JG-AP-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P19">
          <title>VC-JG-LA-CS-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="P20">
          <title>VC-LA-AP-JG-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="12"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were dispensed at least 1 study lens</population>
      <group_list>
        <group group_id="B1">
          <title>AP-CS-LA-JG-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B2">
          <title>AP-JG-CS-VC-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B3">
          <title>AP-LA-VC-CS-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B4">
          <title>AP-VC-JG-LA-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B5">
          <title>CS-AP-VC-JG-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B6">
          <title>CS-JG-AP-LA-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B7">
          <title>CS-VC-LA-AP-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B8">
          <title>CS-LA-JG-VC-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B9">
          <title>JG-AP-LA-VC-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B10">
          <title>JG-CS-VC-LA-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B11">
          <title>JG-LA-CS-AP-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B12">
          <title>JG-VC-AP-CS-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B13">
          <title>LA-AP-JG-CS-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B14">
          <title>LA-CS-AP-VC-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B15">
          <title>LA-JG-VC-AP-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B16">
          <title>LA-VC-CS-JG-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B17">
          <title>VC-AP-CS-LA-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B18">
          <title>VC-CS-JG-AP-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B19">
          <title>VC-JG-LA-CS-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B20">
          <title>VC-LA-AP-JG-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="B21">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="12"/>
            <count group_id="B11" value="12"/>
            <count group_id="B12" value="12"/>
            <count group_id="B13" value="12"/>
            <count group_id="B14" value="12"/>
            <count group_id="B15" value="12"/>
            <count group_id="B16" value="12"/>
            <count group_id="B17" value="12"/>
            <count group_id="B18" value="12"/>
            <count group_id="B19" value="12"/>
            <count group_id="B20" value="12"/>
            <count group_id="B21" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="5.84"/>
                    <measurement group_id="B2" value="26.9" spread="5.78"/>
                    <measurement group_id="B3" value="27.9" spread="4.96"/>
                    <measurement group_id="B4" value="28.0" spread="5.80"/>
                    <measurement group_id="B5" value="30.3" spread="6.06"/>
                    <measurement group_id="B6" value="27.5" spread="4.93"/>
                    <measurement group_id="B7" value="28.2" spread="6.99"/>
                    <measurement group_id="B8" value="26.8" spread="6.58"/>
                    <measurement group_id="B9" value="28.9" spread="5.62"/>
                    <measurement group_id="B10" value="26.6" spread="4.27"/>
                    <measurement group_id="B11" value="27.5" spread="5.04"/>
                    <measurement group_id="B12" value="27.3" spread="5.88"/>
                    <measurement group_id="B13" value="29.1" spread="5.37"/>
                    <measurement group_id="B14" value="26.8" spread="4.37"/>
                    <measurement group_id="B15" value="27.85" spread="5.50"/>
                    <measurement group_id="B16" value="26.3" spread="5.80"/>
                    <measurement group_id="B17" value="27.8" spread="6.29"/>
                    <measurement group_id="B18" value="29.9" spread="6.53"/>
                    <measurement group_id="B19" value="27.6" spread="2.97"/>
                    <measurement group_id="B20" value="30.1" spread="5.11"/>
                    <measurement group_id="B21" value="28.0" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="12"/>
                    <measurement group_id="B16" value="12"/>
                    <measurement group_id="B17" value="12"/>
                    <measurement group_id="B18" value="12"/>
                    <measurement group_id="B19" value="12"/>
                    <measurement group_id="B20" value="12"/>
                    <measurement group_id="B21" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="12"/>
                    <measurement group_id="B16" value="12"/>
                    <measurement group_id="B17" value="12"/>
                    <measurement group_id="B18" value="12"/>
                    <measurement group_id="B19" value="12"/>
                    <measurement group_id="B20" value="12"/>
                    <measurement group_id="B21" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="12"/>
                    <measurement group_id="B16" value="12"/>
                    <measurement group_id="B17" value="12"/>
                    <measurement group_id="B18" value="12"/>
                    <measurement group_id="B19" value="12"/>
                    <measurement group_id="B20" value="12"/>
                    <measurement group_id="B21" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subject in Agreement (Bigger Eyes)</title>
        <description>Subjects' responses to the question &quot;Make my eye look bigger&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
        <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>AP- Etafilcon A</title>
            <description>Subjects that wore the AP investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O2">
            <title>CS- Etafilcon A</title>
            <description>Subjects that wore the CS investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O3">
            <title>JG-etafilcon A</title>
            <description>Subjects that wore the JG investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O4">
            <title>LA-etafilcon A</title>
            <description>Subjects that wore the LA investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O5">
            <title>VC- Etafilcon A</title>
            <description>Subjects that wore the VC investigational lens during any of the 5 period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject in Agreement (Bigger Eyes)</title>
          <description>Subjects' responses to the question &quot;Make my eye look bigger&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
          <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="206"/>
                    <measurement group_id="O4" value="209"/>
                    <measurement group_id="O5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subject in Agreement (Defines Eyes)</title>
        <description>Subjects' responses to the question &quot;Define my eye&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
        <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>AP- Etafilcon A</title>
            <description>Subjects that wore the AP investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O2">
            <title>CS- Etafilcon A</title>
            <description>Subjects that wore the CS investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O3">
            <title>JG-etafilcon A</title>
            <description>Subjects that wore the JG investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O4">
            <title>LA-etafilcon A</title>
            <description>Subjects that wore the LA investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O5">
            <title>VC- Etafilcon A</title>
            <description>Subjects that wore the VC investigational lens during any of the 5 period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject in Agreement (Defines Eyes)</title>
          <description>Subjects' responses to the question &quot;Define my eye&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
          <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="188"/>
                    <measurement group_id="O5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subject in Agreement (Enhance Eyes)</title>
        <description>Subjects' responses to the question &quot;Enhance my overall appearance&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
        <time_frame>15-20 Minutes Post Lens Insertion</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>AP- Etafilcon A</title>
            <description>Subjects that wore the AP investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O2">
            <title>CS- Etafilcon A</title>
            <description>Subjects that wore the CS investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O3">
            <title>JG-etafilcon A</title>
            <description>Subjects that wore the JG investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O4">
            <title>LA-etafilcon A</title>
            <description>Subjects that wore the LA investigational lens during any of the 5 period of the study.</description>
          </group>
          <group group_id="O5">
            <title>VC- Etafilcon A</title>
            <description>Subjects that wore the VC investigational lens during any of the 5 period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject in Agreement (Enhance Eyes)</title>
          <description>Subjects' responses to the question &quot;Enhance my overall appearance&quot; were categorized into a binary variable. If a subject responded &quot;Agrees Somewhat&quot; or &quot;Agrees Strongly&quot; then response=1. If a subject responds &quot;Neither Agrees nor Disagrees&quot;, &quot;Disagrees Somewhat&quot; &quot;Disagrees Strongly&quot; then response=0. The number of subjects with response=1 was reported for each lens.</description>
          <population>Subjects that completed all study visits without a major protocol deviation impacting any of the primary endpoints</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="170"/>
                    <measurement group_id="O5" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 2 hours per subject</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AP-CS-LA-JG-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E2">
          <title>AP-JG-CS-VC-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E3">
          <title>AP-LA-VC-CS-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E4">
          <title>AP-VC-JG-LA-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E5">
          <title>CS-AP-VC-JG-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E6">
          <title>CS-JG-AP-LA-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E7">
          <title>CS-VC-LA-AP-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E8">
          <title>CS-LA-JG-VC-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E9">
          <title>JG-AP-LA-VC-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E10">
          <title>JG-CS-VC-LA-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E11">
          <title>JG-LA-CS-AP-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E12">
          <title>JG-VC-AP-CS-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E13">
          <title>LA-AP-JG-CS-VC</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E14">
          <title>LA-CS-AP-VC-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E15">
          <title>LA-JG-VC-AP-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E16">
          <title>LA-VC-CS-JG-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E17">
          <title>VC-AP-CS-LA-JG</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E18">
          <title>VC-CS-JG-AP-LA</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E19">
          <title>VC-JG-LA-CS-AP</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
        <group group_id="E20">
          <title>VC-LA-AP-JG-CS</title>
          <description>All lenses used in this study were etafilcon A. The lens title correspond to the lens name listed in the protocol registration and refers to various lens variants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charis Lau, Pharm.D., O.D., FAAO</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>(904) 443-1293</phone>
      <email>MLau87@ITS.JNJ.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

